

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeiGene, Ltd.

百濟神州有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 06160)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR – SUPPLEMENTAL INFORMATION

BeiGene, Ltd. (the “**Company**”) refers to the announcement of the Company dated February 4, 2022, relating to the resignation of Mr. Jing-Shyh (Sam) Su (“**Mr. Su**”) as an independent non-executive director on January 31, 2022.

The Company would like to supplement its initial announcement to state that Mr. Su resigned from the Board due to personal reasons to devote more time to other commitments. The decision by Mr. Su to resign was not the result of any disagreement with respect to the operations, policies, or practices of the Company. There is no other material matter in respect of Mr. Su’s resignation that needs to be brought to the attention of shareholders of the Company.

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, February 9, 2022

As of the date of this announcement, the Board of Directors of the Company comprises Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang and Mr. Anthony C. Hooper as Non-executive Directors, and Mr. Timothy Chen, Dr. Margaret Han Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, and Mr. Qingqing Yi as Independent Non-executive Directors.